ReviewFrontiers in pharmacology2026
Natural products targeting the Nrf2 signaling pathway: potential targets and intervention strategies for the prevention and treatment of colorectal cancer.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a highly prevalent gastrointestinal malignancy worldwide, characterised by insidious onset, rapid progression, high tendency for recurrence and metastasis, and resistance to chemotherapy. It poses significant challenges for clinical management and has become a major public health issue threatening human health. Current clinical treatments for CRC remain significantly limited. Traditional chemotherapeutic agents exhibit poor selectivity and pronounced toxic side effects, and long-term use readily induces tumour resistance, resulting in suboptimal therapeutic outcomes. Consequently, the identification of highly effective and safe core therapeutic targets and novel intervention strategies holds significant clinical value. The Nrf2 signalling axis is a core pathway regulating the body's redox homeostasis, inflammatory responses, and the biological behaviour of tumour cells. Abnormal activation of this pathway can drive the proliferation, invasion, and metastasis of CRC cells, inhibit tumour cell apoptosis, and simultaneously mediate the development of chemotherapy resistance, making it a key molecular target involved in the onset and progression of CRC. Due to their widespread sources, structural diversity, low toxicity, and unique ability to exert synergistic regulation across multiple targets and pathways, natural products represent a vital resource for the development of novel anticancer drugs. A substantial body of research has demonstrated that various bioactive natural products can modulate the mode of cell death in CRC cells, inhibit malignant progression, reverse drug-resistant phenotypes, and improve the tumour immune microenvironment by specifically regulating Nrf2 and the expression of its downstream target genes. This article elucidates the core regulatory mechanisms of the Nrf2 signalling axis in the progression of CRC and summarises the anti-CRC effects and molecular mechanisms of various natural products that target this pathway. It analyses the application advantages and translational bottlenecks of natural products, providing a theoretical basis and new research insights for the development of novel natural anti-CRC drugs and the optimisation of clinical combination therapy regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.